302 related articles for article (PubMed ID: 27526711)
1. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.
Chopra M; Biehl M; Steinfatt T; Brandl A; Kums J; Amich J; Vaeth M; Kuen J; Holtappels R; Podlech J; Mottok A; Kraus S; Jordán-Garrote AL; Bäuerlein CA; Brede C; Ribechini E; Fick A; Seher A; Polz J; Ottmüller KJ; Baker J; Nishikii H; Ritz M; Mattenheimer K; Schwinn S; Winter T; Schäfer V; Krappmann S; Einsele H; Müller TD; Reddehase MJ; Lutz MB; Männel DN; Berberich-Siebelt F; Wajant H; Beilhack A
J Exp Med; 2016 Aug; 213(9):1881-900. PubMed ID: 27526711
[TBL] [Abstract][Full Text] [Related]
2. [Influence of donor T(reg) cells on GVHD and hematopoietic reconstitution after allogeneic bone marrow transplantation in mice].
Yang K; Liu QF; Fan ZP; Zhang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):547-52. PubMed ID: 17605863
[TBL] [Abstract][Full Text] [Related]
3. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
6. A TNFR2-Specific TNF Fusion Protein With Improved
Vargas JG; Wagner J; Shaikh H; Lang I; Medler J; Anany M; Steinfatt T; Mosca JP; Haack S; Dahlhoff J; Büttner-Herold M; Graf C; Viera EA; Einsele H; Wajant H; Beilhack A
Front Immunol; 2022; 13():888274. PubMed ID: 35769484
[TBL] [Abstract][Full Text] [Related]
7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.
Zorn E
Semin Cancer Biol; 2006 Apr; 16(2):150-9. PubMed ID: 16431128
[TBL] [Abstract][Full Text] [Related]
10. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
[TBL] [Abstract][Full Text] [Related]
12. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
13. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
14. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.
Rezvani K; Mielke S; Ahmadzadeh M; Kilical Y; Savani BN; Zeilah J; Keyvanfar K; Montero A; Hensel N; Kurlander R; Barrett AJ
Blood; 2006 Aug; 108(4):1291-7. PubMed ID: 16627754
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
16. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
17. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
18. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
19. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
[TBL] [Abstract][Full Text] [Related]
20. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
